

PS Note: Patient deceased on 11th of June 2023, no more new therapy dates

Brief Chemo/IO Infusion Note

DATE: 01/15/2022

PATIENT: Davis, Robert Michael **ID:** SYN153 **DOB:** Dec 26, 1950

TREATMENT: Cycle 4, Day 1 - Docetaxel 60 mg/m² IV

BACKGROUND: Stage IV Lung Adeno (WT, PDL1 90%), Dx 1st of June 2020 (Brain/Bone mets). SRS to brain mets June 2020. 1L Pembrolizumab (June 2020 - Oct 2021), progression in bone/new liver mets. Started 2L Docetaxel 75mg/m² Nov 2021, dose reduced to 60mg/m² after C1 due to Gr 3 neutropenia. Received Pegfilgrastim post C2/C3.

INTERVAL: Tolerating Docetaxel at lower dose better. Fatigue moderate (Gr 2). Neuropathy mild (Gr 1 tingling). No mucositis/diarrhea. Bone pain improved slightly. ECOG 1-2.

ASSESSMENT: Tolerating C4 Docetaxel at 60mg/m². Labs adequate (ANC 2.8, Plt 180). Continue treatment.

PLAN:

1. Administer Docetaxel 60 mg/m² IV per protocol. Pre-meds given (Dex, Ranitidine, Diphenhydramine).
2. Administer Pegfilgrastim Onpro device post-infusion.
3. Antiemetics PRN. Neuropathy monitoring.
4. Restaging CT C/A/P scheduled after this cycle.
5. F/U prior C5.

INFUSION NOTE: Tolerated infusion well, no reaction. Discharged stable.

(Provider Signatures per protocol)